Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $17.5552W HIGH $51.10
Volume
349.48 K
Value Traded
10.75 M
Short % Float
9.72%
+1.32%Week
+1.64%1 Month
+11.67%3 Month
+64.4%6 Month
+20.68%5 Year
+20.68%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.79 B
EPS (TTM)
-0.52
P/E Ratio
-
Ent. Value
1.27 B
Total Shares
46.65 M
Float Shares
29.77 M
Insiders
36.22%
Institutions
64.90%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SEPN Catalyst Timeline
Dated clinical, regulatory and corporate events for Septerna, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Septerna, Inc.
80Total events
9Upcoming
13Tier-1 (high impact)
2024 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Equity OfferingCorporate
Inducement grant of 275,000 stock options to new CMO under Nasdaq Rule 5635(c)(4)
◆Trial InitiationSEP-631Trial
Phase 2b trial initiation planned in CSU
chronic spontaneous urticariasource ↗
◆Poster PresentationSEP-479Presentation
Preclinical characterization of SEP-479 at 2026 ENDO Annual Meeting
Hypoparathyroidismsource ↗
◆Oral PresentationPresentation
Septerna to present at Bank of America Securities Health Care Conference
▲First Patient DosedSEP-479Trial
First participants dosed in Phase 1 SAD/MAD trial of SEP-479
hypoparathyroidismsource ↗
▲First Patient DosedSEP-479Trial
Phase 1 clinical trial initiated for SEP-479
hypoparathyroidismsource ↗
◆Trial InitiationSEP-631Trial
Initiate Phase 2b trial of SEP-631 in CSU
chronic spontaneous urticariasource ↗
▲Full ResultsSEP-631Clinical Data
Positive Phase 1 results for SEP-631 in healthy volunteers
chronic spontaneous urticariasource ↗
▲IND Enabling CompleteSEP-479Preclinical
Completed IND-enabling studies for SEP-479
hypoparathyroidismsource ↗
▲Runway Guidance UpdateCorporate
Cash runway expected to support operations at least into 2029
◆Oral PresentationPresentation
Septerna to present at TD Cowen 46th Annual Health Care Conference
●Oral PresentationSEP-631Presentation
Conference call and webcast to discuss Phase 1 results
mast cell-driven diseasessource ↗
◆Poster PresentationSEP-631Presentation
Poster presentation of Phase 1 data for SEP-631 at 2026 AAAAI Annual Meeting
chronic spontaneous urticaria and other mast cell-driven diseasessource ↗
◆Oral PresentationSEP-631Presentation
Presentation of Phase 1 SAD/MAD results for SEP-631 at AAAAI Annual Meeting
mast cell-driven diseases (e.g., CSU)source ↗
◆Oral PresentationPresentation
Septerna to present at 44th Annual J.P. Morgan Healthcare Conference
◆Trial InitiationSEP-479Trial
Planned initiation of Phase 1 clinical trial for SEP-479
hypoparathyroidismsource ↗
◆Topline ReadoutSEP-631Clinical Data
Initial data from Phase 1 SAD and MAD cohorts for SEP-631
mast cell-driven diseasessource ↗
◆Oral PresentationPresentation
Septerna management to participate in fireside chat at Evercore Healthcare Conference
◆Oral PresentationPresentation
Guggenheim 2nd Annual Healthcare Innovation Conference Fireside Chat
▲Development Candidate NominationSEP-479Preclinical
SEP-479 selected as next-generation oral PTH1R agonist development candidate
hypoparathyroidismsource ↗
▲Trial InitiationSEP-631Trial
Phase 1 clinical trial for SEP-631 initiated in healthy volunteers
mast cell-driven diseasessource ↗
▲First Patient DosedSEP-631Trial
First participants dosed in Phase 1 trial of SEP-631
chronic spontaneous urticaria (CSU) and other mast cell-driven diseasessource ↗
▲First Patient DosedSEP-631Trial
Phase 1 trial of SEP-631 initiated in healthy volunteers
chronic spontaneous urticaria (CSU) and other mast cell-driven diseasessource ↗
▲Partnership / LicenseCorporate
Collaboration with Novo Nordisk became effective
obesity, type 2 diabetes, cardiometabolic diseasessource ↗
◆Development Candidate NominationPreclinical
Selection of next-generation PTH1R agonist development candidate
hypoparathyroidismsource ↗
▲Partnership / LicenseCorporate
Septerna and Novo Nordisk announce collaboration for oral small molecule GPCR therapies
obesity, type 2 diabetes, other cardiometabolic diseasessource ↗
▲Milestone PaymentCorporate
Upfront and near-term milestone payments >$200 million from Novo Nordisk
obesity, type 2 diabetes, other cardiometabolic diseasessource ↗
●Other Regulator MilestoneEx-US Regulatory
Closing expected in Q2 2025 subject to HSR Act clearance
Past FDA Catalysts and PDUFA Decisions
How SEPN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$42M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 88%
Micro Cap(rank 581 of 660)
Percentile Rank
Septerna, Inc. faces pipeline headwinds (23/100), with $106M risk-adjusted pipeline value, led by SEP-631 in Undisclosed (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SEP-631 Small moleculeCompletedNCT07069036 | Undisclosed | Phase 1 | COMPLETED | 120 | Dec 18, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every SEPN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SEP-631 | chronic spontaneous urticaria | Phase 1 | 2026-05-11 | well tolerated; demonstrated a pharmacokinetic profile supportive of once-daily oral dosing; produced robust, dose-dependent suppression of icatibant-induced skin wheal formationRead More | Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic SpontaneouRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Long Daniel D.Officer (SVP, Drug Discovery) | Option | 3,333 99,745 held | $2.76 | 09/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SEPN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 2 % (11.1 %) | 234.29 M | 7.00 M |
SEPN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SEPN ranks across every disease it competes in
Competitive Position is a premium feature
See how SEPN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSEPN News
SEPNSepterna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Septerna, Inc. has granted a non-qualified stock option to Dr. Rajiv Patni, its new Chief Medical Officer, as part of its 2026 Inducement Plan. The grant, effective September 8, 2026, allows Dr. Patni to purchase 275,000 shares at an exercise price of $37.37 per share. The option will vest over four years, contingent on his continued employment.
Read more →SEPNSepterna to Participate in Upcoming Investor Conferences
Septerna, Inc. has announced its participation in two upcoming investor conferences in September 2026. The company will engage in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 8 and at the Cantor Global Healthcare Conference on September 10. Live webcasts of these presentations will be available on their website.
Read more →SEPNSepterna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
Septerna, Inc. has appointed Dr. Rajiv Patni as Chief Medical Officer. Dr. Patni brings extensive experience in the biotechnology sector, which is expected to bolster Septerna's efforts in G protein-coupled receptor drug discovery. This strategic move aims to enhance the company's leadership and innovation in the field.
Read more →SEPN▲ +22.9%on this news
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
Septerna has reported progress in its business operations, particularly highlighting the ongoing Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist. The trial's pharmacokinetic profile indicates that once-daily dosing is feasible. Additionally, the company's robust cash position of $516.5 million is expected to sustain its operational plans through at least 2029.
Read more →SEPNSepterna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
Septerna is set to present the preclinical characterization of SEP-479, an oral PTH1R agonist aimed at treating hypoparathyroidism. This presentation will take place at the 2026 ENDO Annual Meeting. Details about the drug's efficacy and safety profile are expected to be discussed during the event.
Read more →SEPNSepterna Highlights Business Progress and Reports First Quarter 2026 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support
Septerna, Inc. has highlighted significant progress in its clinical pipeline and reported financial results for Q1 2026. The company has achieved positive Phase 1 data for SEP-631, enabling its advancement into Phase 2b trials for chronic spontaneous urticaria. Additionally, the initiation of a Phase 1 trial for SEP-479 marks a notable expansion in their experimental offerings. With a robust cash position of $522.1 million, Septerna is well-capitalized to support its operational plans through at least 2029.
Read more →SEPNSepterna to Present at Bank of America Securities Health Care Conference
Septerna, Inc. will present at the Bank of America Securities Health Care Conference on May 12, 2026. CEO Jeffrey Finer will discuss the company's advancements in G protein-coupled receptor drug discovery. The presentation will be available via a live webcast and archived for 30 days. Septerna focuses on developing therapies for unmet medical needs.
Read more →SEPNSepterna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Septerna has initiated a Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist aimed at treating hypoparathyroidism. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. Results are expected by late 2026 or early 2027, with SEP-479 potentially offering a more convenient treatment option compared to current therapies.
Read more →SEPNSepterna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026
Septerna, Inc. reported significant milestones in its pipeline progress alongside financial results for Q4 and FY 2025. Positive Phase 1 data for SEP-631 indicates its potential in treating chronic spontaneous urticaria, with plans to initiate Phase 2b development by late 2026. Financially, the company maintains a strong cash position of $548.7 million, expected to support operations into 2029. However, increasing net losses and operational costs present challenges as the company advances its drug candidates. The pipeline also includes SEP-479, progressing toward Phase 1 initiation soon.
Read more →SEPNSepterna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
Septerna, Inc. announced positive Phase 1 trial results for SEP-631, an oral MRGPRX2 negative allosteric modulator. The trial demonstrated effective inhibition of mast cell activation, supporting its advancement into Phase 2 for chronic spontaneous urticaria. SEP-631 was well-tolerated, with plans to explore additional mast cell-driven diseases.
Read more →SEPN▲ +10.2%on this news
Septerna to Present at TD Cowen 46th Annual Health Care Conference
Septerna, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. CEO Jeffrey Finer will discuss the company's advancements in G protein-coupled receptor (GPCR) drug discovery. The presentation will be available via live webcast and archived for 30 days. Septerna focuses on developing novel therapies for unmet medical needs.
Read more →SEPNSepterna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 10, 2026
Septerna, Inc. has granted an inducement stock option award to Mark A. Wilson, its Chief Legal Officer, as part of its 2026 Inducement Plan. The award consists of 165,000 shares with an exercise price of $25.41, vesting over four years. This move is in compliance with Nasdaq Listing Rule 5635(c)(4) and aims to enhance the company's leadership team.
Read more →SEPNSepterna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
Septerna, Inc. will present data from its Phase 1 clinical trial of SEP-631 at the 2026 AAAAI Annual Meeting. SEP-631 is a selective oral small molecule designed to target MRGPRX2 for treating chronic spontaneous urticaria and other mast cell-driven diseases. The presentation will take place on March 1, 2026, in Philadelphia.
Read more →SEPNPioneering a New Era of GPCR Drug Discovery J.P. Morgan Healthcare Conference 2026 January 2026 Nasdaq: SEPN Forward-Looking Statements This presentation contains express or implied forward looking statements of Septerna
Septerna is set to pioneer GPCR drug discovery, announcing advancements in its drug pipeline at the J.P. Morgan Healthcare Conference 2026. The company plans to initiate a Phase 1 clinical trial for its oral PTH1R agonist, SEP-479, which aims to address the unmet needs in managing hypoparathyroidism. Additionally, Septerna is collaborating with Novo Nordisk to develop oral therapies for metabolic diseases, leveraging its proprietary Native Complex Platform to enhance drug discovery capabilities. However, these forward-looking statements carry inherent risks, particularly related to regulatory processes and clinical trial outcomes.
Read more →SEPNSepterna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Septerna, Inc. has appointed Mark A. Wilson as Chief Legal Officer, bringing over 25 years of experience in the pharmaceutical and biotech sectors. His expertise in intellectual property and corporate governance is expected to bolster Septerna's strategic initiatives. Wilson previously held senior roles at Nektar Therapeutics and is enthusiastic about contributing to Septerna's mission in GPCR drug discovery.
Read more →SEPNSepterna to Present at 44th Annual J.P. Morgan Healthcare Conference
Septerna, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. CEO Jeffrey Finer will discuss the company's advancements in GPCR drug discovery and its diverse pipeline of drug candidates. The presentation will be available via a live webcast on the company's website.
Read more →SEPNSepterna to Participate in 8th Annual Evercore Healthcare Conference
Septerna, Inc. will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025. The event will feature a fireside chat with management, highlighting the company's advancements in G protein-coupled receptor drug discovery. A live webcast of the presentation will be accessible on their website, with an archive available for 30 days.
Read more →SEPNSepterna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
Septerna, Inc. reported significant advancements in its drug development pipeline, including the selection of SEP-479 as a leading candidate for hypoparathyroidism and the continuation of a Phase 1 trial for SEP-631 targeting mast cell-driven diseases. The company also highlighted its robust financial position, with $561.6 million expected to sustain operations through at least 2029. Upcoming milestones are anticipated in the first half of 2026.
Read more →About Septerna, Inc.
Headquarters250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next SEPN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime